Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06859073 · ClinicalTrials.gov registry record · Phase 1

A Research Study to Evaluate the Safety of NNC4004-0002 When Given to Participants With Asymptomatic Hyperuricemia

A Phase 1 study of Healthy Volunteers and Hyperuricemia, sponsored by Novo Nordisk A/S.

Recruiting
Registry status
Phase 1
Development phase
60
Enrollment target
2
Study locations

NCT06859073 is a Phase 1 study of Healthy Volunteers and Hyperuricemia that is actively recruiting participants, run by Novo Nordisk A/S. The registered enrollment target is 60 participants, below the 482-participant average among 283 other Healthy Volunteers trials with a reported enrollment target (88% lower). The trial reports 2 study locations across 2 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06859073, a Phase 1 study of Healthy Volunteers and Hyperuricemia, is actively recruiting participants, sponsored by Novo Nordisk A/S.

RECRUITING
Registry status
Phase 1
Development phase
60 participants
Enrollment target
2
Study locations

Study Summary

This study will evaluate an investigational drug called NNC4004-0002. "Investigational" means NNC4004-0002 has not been approved for sale/ for clinical use or for the use described in this study/ by any regulatory authority. Its use in this study is experimental. This will be the first time that NNC4004-0002 will be given to human. This study will be testing the ability of the study medicine to lower serum uric acid. The main aim of this study will be to see if the new study medicine is safe and tolerated by the body after a single dose of study medicine in adults with asymptomatic hyperuricemia. Participants will either get NNC4004-0002 (the study medicine), or saline. Which treatment the participant get will be decided by chance. The participant will get the medicine as an injection under their skin. Depending on the dose they will receive, participant may need more than one injection. The study will last for about 19 months in total. The participant will take part in the study for about 7 months. Participant will have approximately 14 visits to the clinic and one of them will be a 4 night in-house stay.

Conditions Studied

Healthy Volunteers Hyperuricemia

Interventions

  • DRUG Placebo
  • DRUG NNC4004-0002

Study Locations (2)

California

  • PAREXEL Glendale/LA EPCU - Glendale

Maryland

  • PAREXEL Intl - EPCU-Baltimore - Baltimore

Trial Details

FieldValue
Enrollment Target 60 participants
Start Date 2024-11-13
Est. Completion 2026-06-01
Phase Phase 1

Sponsor

Novo Nordisk A/S

431 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06859073

The ClinicalTrials.gov registry entry for NCT06859073 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 482-participant average among 283 other Healthy Volunteers trials with a reported enrollment target (88% lower). The listed sponsor is Novo Nordisk A/S, which has 431 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Healthy Volunteers appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT06859073 reports 2 study locations spanning 2 distinct geographic areas - top geographies include California, Maryland.

Frequently Asked Questions

What is clinical trial NCT06859073 about?

NCT06859073 is a clinical study titled "A Research Study to Evaluate the Safety of NNC4004-0002 When Given to Participants With Asymptomatic Hyperuricemia". This study will evaluate an investigational drug called NNC4004-0002. "Investigational" means NNC4004-0002 has not been approved for sale/ for clinical use or for the use described in this study/ by any regulatory authority. Its use in this study is experimental. This will be the first time that NNC...

What is the current status of trial NCT06859073?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 60 participants. The study started on 2024-11-13. Estimated completion is 2026-06-01.

What conditions does trial NCT06859073 study?

This clinical trial studies the following conditions: Healthy Volunteers, Hyperuricemia.

What interventions are being tested in trial NCT06859073?

The interventions under investigation include: Placebo (DRUG), NNC4004-0002 (DRUG).

Who is sponsoring clinical trial NCT06859073?

This trial is sponsored by Novo Nordisk A/S, which has 431 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06859073 being conducted?

This trial has 2 study locations across California, Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Healthy Volunteers

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Healthy Volunteers

All registered trials for this condition

Hyperuricemia

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.